This week, the ratings of three Pharmaceutical stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Keep Reading →
August 30 - News
In the financial world, there are a multitude of gauges investors can use to watch publicly traded companies. A couple of the best are hedge fund and insider trading interest.
Keep Reading →
August 30 - News
Today, let's look at SAC Capital Advisors, run by Steven Cohen.
Keep Reading →
August 29 - Hedge Funds
The idea inspired me to issue my own questions about the company, using the questions as a crutch to explain my position.
Keep Reading →
August 28 - News
In today’s marketplace, there are tons of gauges market participants can use to track their holdings.
Keep Reading →
August 28 - News
While I do think it's possible that MannKind Corporation (NASDAQ:MNKD)'s inhaled insulin device, Afrezza, will be approved by the Food and Drug Administration, I do have serious...
Keep Reading →
August 22 - News
In the 21st century investor’s toolkit, there are dozens of metrics investors can use to track Mr. Market.
Keep Reading →
August 22 - News
MannKind Corporation (NASDAQ:MNKD) has gotten one of the biggest votes of confidence we've seen from the smart money, out of the entire stock market universe and the 500+ elite...
Keep Reading →
August 22 - News
The MannKind Corporation has announced that as per the agreement to the 1 July 2013, facility contract, between MNKD and the Deerfield Private Design Fund II.
Keep Reading →
August 20 - News
It's no wonder that plenty of companies are developing diabetes drugs. There are more than 370 million people with diabetes worldwide.
Keep Reading →
August 20 - News
After my article on MannKind Corporation (NASDAQ:MNKD) earlier this week, a reader wasn't too happy about my view that the company was overvalued given the most recent phase ...
Keep Reading →
August 19 - News
With the SPDR S&P Biotech Index up 34% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
August 19 - News
While the major indexes pulled back this week, their declines paled in comparison to the huge drops experienced by a handful of health-care stocks.
Keep Reading →
August 19 - News
Let's start with Vical Incorporated (NASDAQ:VICL). The biotech shed more than half of its value after abandoning its once promising Allovectin program.
Keep Reading →
August 19 - News
Yum! Brands, Inc. (NYSE:YUM)'s Taco Bell is keeping the Doritos-dusted taco shells coming.
Keep Reading →
August 17 - News
MannKind's positive take on interim Phase III data for its inhaled insulin Afrezza has a big sweetener tied to it.
Keep Reading →
August 16 - News
MannKind Corporation (NASDAQ:MNKD) ended up more than 10% on Wednesday, after the biotech announced positive results for two phase 3 trials testing its inhaled insulin Afrezza...
Keep Reading →
August 15 - News
The long promise of insulin that diabetics can inhale appears to be moving closer to the market.
Keep Reading →
August 14 - News
Nothing is for certain in biotech, but it looks to me like the extended phase 3 program has an extremely high likelihood of coming up positive.
Keep Reading →
August 12 - News
In a companion article a few days ago, I predicted that MannKind Corporation (NASDAQ:MNKD)'s extended phase 3 program for its inhaled insulin, Afrezza, is likely to produce ...
Keep Reading →
August 12 - News
With luck, Santa Clarita’s MannKind Corporation (NASDAQ:MNKD) hopes to have FDA approval by April of next year of its innovative diabetes treatment – Afrezza.
Keep Reading →
August 1 - News
Today, let's look at the California State Teachers' Retirement System ("CalSTRS"), a major pension fund that's celebrating its 100th anniversary in 2013.
Keep Reading →
July 29 - News
The news flow from biotech companies might slow down during the summer, but it won't stop.
Keep Reading →
July 1 - News
An entity with deep pockets is looking to buy boatloads of Pfizer Inc. (NYSE:PFE) stock. And we're talking yacht-sized boatloads -- not canoe-sized ones.
Keep Reading →
July 1 - News
Netflix, Inc. (NASDAQ:NFLX) has been a poster boy for market success in 2013.
Keep Reading →
June 25 - News
An FDA approval is the Holy Grail for biotechnology companies and their investors – but a successful launch is the most momentous in producing long-term gains.
Keep Reading →
June 19 - News
The share prices of MannKind Corporation (NASDAQ:MNKD) had been traded in the price range of $5.70 and $7.62 per share on Tuesday.
Keep Reading →
June 19 - News
Investors can never predict whether the market will rise or fall on any given day, but lately, a pretty good bet has been to expect some substantial volatility in one direction...
Keep Reading →
June 19 - News
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company MannKind Corporation...
Keep Reading →
June 18 - News
It's understandably very tempting for people with inside information to trade biotech stocks.
Keep Reading →
June 17 - News
You could say that MannKind Corporation (NASDAQ:MNKD) is treading water a bit these days -- at least from the outside perspective.
Keep Reading →
June 14 - News
According to most stock holders, hedge funds are viewed as underperforming, old financial vehicles of the past.
Keep Reading →
June 14 - News
How can you double your investment literally overnight? Buy stocks of the right biotech companies.
Keep Reading →
June 13 - News
In the eyes of most traders, hedge funds are seen as worthless, old financial tools of the past.
Keep Reading →
June 10 - News
In the financial world, there are plenty of indicators market participants can use to track publicly traded companies.
Keep Reading →
June 6 - News
If you'd owned these three biotech companies at the beginning of the year, you're sitting on around a triple compared to a relatively smaller-but-still-impressive 34% increase...
Keep Reading →
June 3 - News
If you'd ask most shareholders, hedge funds are assumed to be underperforming, old investment tools of the past.
Keep Reading →
June 3 - News
If you'd ask most shareholders, hedge funds are assumed to be slow, outdated investment tools of the past.
Keep Reading →
May 31 - News
Shares of MannKind Corporation (NASDAQ:MNKD) have nearly tripled over the last year.
Keep Reading →
May 24 - News
Keeping a close eye on two particular classes of investors can tell you a lot about how stocks might move in the future.
Keep Reading →
May 23 - News
An enormous call trade tops today's option activity in biopharmaceutical company MannKind Corporation (NASDAQ:MNKD) as takeover speculation rises.
Keep Reading →
May 22 - News
MannKind Corporation (NASDAQ:MNKD) took one giant leap over the past few days.
Keep Reading →
May 19 - News
What's the source of your investment strategy? Many look to great investors like Warren Buffett for guidance on how to invest.
Keep Reading →
May 13 - News
Perennial underdog MannKind Corporation (NASDAQ:MNKD) could be on its countdown to liftoff.
Keep Reading →
May 10 - News
They're demanding. They take risks -- but only calculated ones. And they ask lots of penetrating questions to understand as much as possible before putting a dime on the line.
Keep Reading →
April 22 - News
MannKind Corporation (NASDAQ:MNKD) was in 8 hedge funds' portfolio at the end of December. MNKD shareholders have witnessed an increase in hedge fund interest of late.
Keep Reading →
April 13 - News
Investors have been as clear as they can be about what they see as their ideal situation.
Keep Reading →
April 10 - News
According to most investors, hedge funds are perceived as worthless, old financial tools of years past.
Keep Reading →
April 8 - News
They don't have any products on the market. They have little or no revenue. Earnings? Nada. Many people are betting that they will fail.
Keep Reading →
April 4 - News
In the 21st century investor’s toolkit, there are a multitude of indicators investors can use to track publicly traded companies.
Keep Reading →
April 2 - News
